Coya Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Filed March 22, 2023, reporting an agreement entered into on March 16, 2023. Coya Therapeutics is developing COYA 302, a proprietary biologic combination product candidate for certain neurodegenerative diseases. COYA 302 combines Coya’s low-dose IL-2 product, COYA 301, with Dr. Reddy’s Laboratories’ proposed Abatacept biosimilar.
Material Definitive Agreement
On March 16, 2023, Coya entered into an exclusive License and Supply Agreement with Dr. Reddy’s Laboratories Limited. The agreement becomes effective April 1, 2023 and covers development and commercialization of COYA 302 in the United States, Canada, Mexico, South America, the European Union, the United Kingdom, and Japan.
| Item | Terms |
|---|---|
| Upfront payment | $350,000 one-time, non-refundable payment due within 30 days of execution |
| Milestones | Up to approximately $22.7 million in development, regulatory, and sales milestones, plus a low-six-figure milestone payment for each additional indication |
| Royalties to DRL | Single-digit royalties on net sales in Coya’s licensed territories |
| Royalties to Coya | Single-digit royalties on net sales by DRL in territories not granted to Coya |
| Term | Initial 25-year term, automatically renewing for successive two-year terms unless either party provides notice of non-renewal |
Responsibilities, Outlook, and Risks
- Coya retains responsibility for development of COYA 302 and regulatory approval in its territories.
- DRL is responsible for manufacturing and supplying the proposed Abatacept biosimilar and for regulatory approval in its respective territories.
- Within 36 months before the anticipated regulatory application date, the parties will negotiate in good faith the terms for commercial supply quantities.
- The agreement includes termination rights for cause, insolvency, and regulatory approval issues, together with customary exclusivity, indemnification, confidentiality, representations, warranties, and covenants.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial statement metrics, and no formal financial guidance.
- Development, regulatory approval, manufacturing supply, milestone obligations, and commercialization remain subject to significant uncertainty.
Most Important Facts to Verify
- Confirm the agreement became effective on April 1, 2023 and review the complete license terms when filed as an exhibit in a subsequent periodic report.
- Assess Coya’s ability to fund the $350,000 upfront payment, future development costs, and potential milestone payments.
- Monitor clinical, regulatory, and commercial progress for COYA 302 and the proposed Abatacept biosimilar.
- Evaluate DRL’s manufacturing and supply obligations, including the terms to be negotiated for commercial quantities.
- Review the agreement’s termination, territory, royalty, exclusivity, and additional-indication provisions.